Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares saw strong trading volume on Thursday . 3,113,031 shares traded hands during trading, an increase of 217% from the previous session’s volume of 980,822 shares.The stock last traded at $7.64 and had previously closed at $6.90.

A number of research analysts recently weighed in on the company. FBR & Co reaffirmed a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, June 12th. Wedbush reaffirmed a “neutral” rating and set a $4.00 price target on shares of Raptor Pharmaceutical Corp. in a research note on Friday, May 6th. Zacks Investment Research downgraded Raptor Pharmaceutical Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. Cowen and Company reaffirmed a “buy” rating and set a $8.00 price target on shares of Raptor Pharmaceutical Corp. in a research note on Friday. Finally, Citigroup Inc. downgraded Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and upped their price target for the stock from $6.00 to $8.00 in a research note on Monday, August 8th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.21.

The stock’s 50-day moving average is $6.21 and its 200-day moving average is $5.08. The firm’s market capitalization is $611.64 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The business earned $32.05 million during the quarter, compared to the consensus estimate of $28.52 million. The firm’s revenue for the quarter was up 37.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.17) earnings per share. On average, equities research analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.90) EPS for the current year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. raised its stake in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 at the end of the most recent reporting period.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.